Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Glioma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of high grade glioma based on tissue biopsy

Exclusion criteria

Treatment and study plan

Primary outcomes

The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

Time frame: April 2019 - December 2021

The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

Sponsors and collaborators

Lead sponsor

Hellenic Cooperative Oncology Group

Other

Registry information

Official study title

Molecular Characterization of Gliomas Using a Broad NGS Panel

Important dates

Study start: 2015
Primary completion: 2021
Study completion: 2022
First posted: Aug 3, 2022
Registry last updated: Aug 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed